Introduction
============

Gastric cancer is the third most frequently diagnosed cancer type, and has been the leading cause of cancer-related death in less-developed countries ([@b1-mmr-17-05-6387]). Although advances in therapeutic strategies such as surgery and systemic chemotherapy, have improved the clinical outcomes for gastric cancer patients, the prognosis of these patients remains poor because of frequent cancer recurrence ([@b2-mmr-17-05-6387]). Nevertheless, due to the encouraging development in newly targeted therapies, such a disappointing clinical condition has been improving. Trastuzumab, the first targeted antibody against human epidermal growth factor receptor 2 (HER2), has been approved for the treatment of patients with HER2-positive metastatic gastric cancer ([@b3-mmr-17-05-6387]). However, even with trastuzumab resistance, gastric cancer almost inevitably progresses, as the tumors become resistant to trastuzumab after an initial period of clinical benefits ([@b4-mmr-17-05-6387]). Mechanisms leading to trastuzumab resistance in breast cancer, such as cross-talk between HER2 and other intracellular kinase receptors, have been described recently ([@b5-mmr-17-05-6387]), however, the underlying mechanisms of trastuzumab resistance in gastric cancer remain largely unknown.

Cancer cells are able to activate alternative survival pathways yielding drug resistance in response to chemotherapy, and thereby leads to the chemotherapeutic treatment failure ([@b6-mmr-17-05-6387]). Since drug resistance is a common cause limiting the efficacy of cancer treatment, several mechanisms are elucidated to be responsible for the resistance development, such as increased rates of drug efflux, apoptosis resistance, and microRNAs (miRNAs) mediated overexpression of many drug resistance-related genes ([@b7-mmr-17-05-6387]). Microarray technology, a high-throughput platform that analyzes gene expression, in combination with bioinformatics analysis has been widely used as a promising tool to acquire gene signature during tumorigenesis or drug resistance, and identify prognostic biomarkers in cancer patients ([@b8-mmr-17-05-6387]--[@b10-mmr-17-05-6387]). Abnormal expression patterns of drug resistance-related genes commonly play important roles in drug resistance ([@b11-mmr-17-05-6387]), thus, exploring and identifying the critical drug resistance-related genes based on microarray analysis would have a significant impact.

Therefore, in the present study, we sought to identify the potential genes that promote trastuzumab resistance in gastric cancer through retrieving microarray data from public databases and comprehensive bioinformatics analysis.

Materials and methods
=====================

### Microarray data

The gene expression profiles of GSE26899, GSE77346, GSE54129, and GSE65801 were obtained from the Gene Expression Omnibus (GEO; [www.ncbi.nlm.nih.gov/geo](www.ncbi.nlm.nih.gov/geo)). In detail, GSE26899 dataset is consisted of 96 clinical gastric tumor tissues and 12 adjacent normal tissues; GSE77346 dataset is consisted of 1 trastuzumab-sensitive cell line and 4 trastuzumab-resistant cell lines ([@b12-mmr-17-05-6387]); GSE54129 includes 111 human gastric cancer tissues and 21 non-cancerous tissues; GSE65801 contains 32 gastric cancer tissues and 32 paired non-cancerous tissues ([@b13-mmr-17-05-6387]).

### Processing of microarray data

The raw microarray data files of the datasets downloaded from the GEO website were subsequently analyzed via using the GEO2R ([www.ncbi.nlm.nih.gov/geo/geo2r/](www.ncbi.nlm.nih.gov/geo/geo2r/)), an online tool comparing two or more groups of samples in the same experimental setting ([@b14-mmr-17-05-6387]). False Discovery Rate (FDR) of P-value adjusted (adj. P) to 0.05 and \|logFC\|\>1 were set as the cut-off criteria.

### Functional and pathway enrichment analyses

Gene ontology (GO) analysis is a commonly used approach for functional studies with three ontologies including biological process, molecular function, and cellular component ([@b15-mmr-17-05-6387]), while Kyoto Encyclopedia of Genes and Genomes (KEGG) is a knowledge base for the systematic study of gene functions ([@b16-mmr-17-05-6387]). To study the functional annotations of differentially expressed genes (DEGs), we next employed Database for Annotation, Visualization and Integrated Discovery (DAVID, [david.abcc.ncifcrf.gov/](david.abcc.ncifcrf.gov/),) to process the GO and KEGG analyses of DEGs identified in gastric cancer samples. P\<0.05 was set as the threshold.

### Protein-protein interaction (PPI) network construction and module analysis

The Search Tool for the Retrieval of Interacting Genes (STRING), an online database ([string-db.org](string-db.org)) designed to evaluate PPI information, covers 9,643,763 proteins from more than 2,000 organisms, which was used to construct the PPI. To evaluate the interactive associations of DEGs identified from GSE26899, we mapped these DEGs to the STRING (version 10.5) database. Confidence score \>0.4 was selected as significant. PPI networks were constructed by STRING and visualized by Cytoscape. Subsequently, the plug-in Molecular Complex Detection (MCODE) was employed to screen the modules of PPI networks in Cytoscape with the threshold set as follows: MCODE scores \>10.

### Survival analysis of collagen type IV α1 chain (COL4A1)

To evaluate the association between *COL4A1* level and its clinical outcomes, Kaplan-Meier plotter (KM plotter; [www.kmplot.com](www.kmplot.com)), an online survival analysis tool, was performed. KM plotter is capable of assessing the effect of 54,675 genes on overall survival via using 10,188 cancer samples including 4,142 breast, 1,648 ovarian, 2,437 lung, and 1,065 gastric cancer patients ([@b17-mmr-17-05-6387]). Patients with gastric cancer were separated into high- and low-expression groups according to the level of COL4A1, and the overall survival was then analyzed. The hazard ratio (HR) with 95% confidence intervals and log rank P-value were calculated.

### Analysis of COL4A1 by geneMANIA and coremine

GeneMANIA, an online tool ([www.genemania.org/](www.genemania.org/)), can be used to generate hypotheses of gene function, analyze gene lists, and prioritize genes for functional assays ([@b18-mmr-17-05-6387]). After selecting Homo sapiens from the nine optional organisms, *COL4A1* was entered into the search bar and the results were then collected. Annotation of biological processes involving *COL4A1* was performed by consulting the Coremine Medical online database ([www.coremine.com/medical/](www.coremine.com/medical/)).

### Prediction of miRNAs

To predict the miRNAs targeting the mRNA of *COL4A1*, miRWalk (version 2.0, [zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/](zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/)), an online platform supplying information about predicted and experimentally validated miRNA-target interactions, was then employed ([@b19-mmr-17-05-6387]). Herein, nine prediction programs (miRWalk, miRanda, miRDB, miRNAMap, Pictar2, PITA, RNA22, RNAhybrid and Targetscan) were selected. These predicted miRNAs were then overlapped by at least seven programs, and selected for further analysis. Pathway enrichment analysis of these miRNAs was performed by using the DIANA-mirPath web server (snf-515788.vm.okeanos.grnet.gr/index.php?r=mirpath) ([@b20-mmr-17-05-6387]).

### Statistical analysis

SPSS 22.0 software (IBM Corp., Armonk, NY, USA) was used to analyze data. Two tailed Student\'s t-test was used to compare the two groups. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Module acquisition based on the DEGs identified in gastric cancer tissues

Drug resistance-related genes identified from *in vitro* drug-induced resistant models may simply represent transcriptional changes, thus, complementary agents targeting these genes are usually failure to translate into clinical practice ([@b21-mmr-17-05-6387]). Because drug resistance acquisition can arise before the malignant transformation stage ([@b22-mmr-17-05-6387]), the genes playing important roles in tumorigenesis and drug resistance is thereby more likely to be critical for resistance occurrence. Therefore, we first identified 509 DEGs in gastric cancer tissues from the GSE26899 dataset using a 2-fold-change and adj. P\<0.05 as the threshold cutoff. Among these DEGs, the expression of these 172 genes was significantly upregulated, while that of 337 genes was significantly downregulated in cancer tissues ([Fig. 1A](#f1-mmr-17-05-6387){ref-type="fig"}). To explore the potential roles of these significantly upregulated DEGs, GO and KEGG pathway analyses, which can provide valuable insights regarding protein function, were performed ([@b23-mmr-17-05-6387]). As shown in [Fig. 1B](#f1-mmr-17-05-6387){ref-type="fig"}, GO results showed that these significantly upregulated DEGs were largely associated with extracellular region part, collagen, extracellular matrix, and cell or biological adhesion processes. KEGG results also consistently revealed that these DEGs were highly enriched in extracellular matrix-receptor interaction and focal adhesion pathways ([Fig. 1C](#f1-mmr-17-05-6387){ref-type="fig"}). Based on further DEGs analysis with the STRING database, the PPI network of these DEGs, which contained 505 nodes and 1,207 edges, was subsequently constructed. Using the MCODE plug-in in Cytoscape, we obtained the module with the highest score ([Fig. 2A](#f2-mmr-17-05-6387){ref-type="fig"}), and also performed a cluster analysis of these genes in the module ([Fig. 2B](#f2-mmr-17-05-6387){ref-type="fig"}). The module with the highest score was selected based on these DEGs identified from gastric cancer tissues via bioinformatics methods.

### Expression of COL4A1, overexpressed in gastric cancer tissues, is also upregulated in trastuzumab-resistant gastric cancer cells

To further explore the potential genes contributing to trastuzumab resistance, we retrieved GSE77346 data, a microarray dataset consisted of one trastuzumab-sensitive gastric cancer cell line and four trastuzumab-resistant gastric cancer cell lines ([@b12-mmr-17-05-6387]). After screening the significantly upregulated DEGs in trastuzumab-resistant cancer cells, *COL4A1*, one of hub genes in the selected module ([Fig. 2A](#f2-mmr-17-05-6387){ref-type="fig"}), was also found to be significantly upregulated in trastuzumab-resistant cells ([Fig. 3A](#f3-mmr-17-05-6387){ref-type="fig"}), suggesting *COL4A1* might be important in both tumorigenesis and trastuzumab resistance. Since the gene expression is not always consistent with its protein amount ([@b24-mmr-17-05-6387]), further validation of *COL4A1* protein level in clinical gastric cancer tissues is quite necessary. By employing the Human Protein Atlas database, an online tool analyzing protein level from clinical specimens, we observed that COL4A1 was positively expressed in gastric cancer tissue, but negatively expressed in normal gastric tissue ([Fig. 3B](#f3-mmr-17-05-6387){ref-type="fig"}). Two other datasets, including GSE54129 and GSE65801 were also used to validate the mRNA level of *COL4A1*, which was indeed significantly upregulated in clinical gastric cancer samples ([Fig. 3C and D](#f3-mmr-17-05-6387){ref-type="fig"}). To investigate potential regulation mechanisms of *COL4A1* in gastric cancer, the genomic alteration of *COL4A1* in The Cancer Genome Atlas (TCGA) cohort was analyzed using the cBioPortal ([www.cbioportal.org/](www.cbioportal.org/)) ([@b25-mmr-17-05-6387]). As shown in [Fig. 3E](#f3-mmr-17-05-6387){ref-type="fig"}, the amplification, missense mutation, truncating mutation, and deletion of *COL4A1* accounted for 4.3, 4.8, 2.0, and 0.5% of stomach adenocarcinoma cases, respectively. The prognostic value of COL4A1 in patients with gastric cancer was analyzed using the KM plotter according to the low and high expression of COL4A1. As shown in [Fig. 3F](#f3-mmr-17-05-6387){ref-type="fig"}, the high mRNA level of *COL4A1* \[HR 1.56 (1.31--1.86)\] was associated with poor overall survival of gastric cancer patients. Altogether, these data suggest that *COL4A1* is a potential gene candidate that promotes the development of gastric cancer and subsequent trastuzumab resistance.

### Drug resistance function of COL4A1 is validated by protein/gene interactions and biological process annotation analyses

As a user-friendly web interface for functional prediction of genes, GeneMANIA has been widely used as an effective tool to predict and explore drug resistance-related genes ([@b18-mmr-17-05-6387]). Accordingly, *COL4A1* showed interactions with 20 proteins/genes; among these 6 genes were involved in conferring drug resistance in cancer ([Fig. 4A](#f4-mmr-17-05-6387){ref-type="fig"}). The mRNA expression of these 6 genes in gastric cancer cells and trastuzumab-resistant gastric cancer cells were also evaluated using the microarray data of GSE77346. As shown in [Fig. 4B](#f4-mmr-17-05-6387){ref-type="fig"}, the mRNA level of angiopoietin 2 (*ANGPT2*), *COL3A1, COL15A1*, and secreted protein acidic and cysteine rich (*SPARC*) were upregulated in trastuzumab-resistant gastric cancer cells. Among these genes, *COL4A1* co-expressed and co-localized with *ANGPT2*, collagen type VI α 3 chain (*COL6A3*), and *SPARC*, respectively. It has been reported bevacizumab resistance in glioblastoma and doxorubin resistance in liver cancer are largely mediated by an enforcement of ANGPT2/TIE2 signaling ([@b26-mmr-17-05-6387],[@b27-mmr-17-05-6387]). Additionally, overexpression of *COL6A3*, one of the most highly upregulated genes in oxaliplatin and cisplatin resistant ovarian cancer cells, has also been recognized to confer cisplatin resistance in sensitive cancer cells ([@b28-mmr-17-05-6387]). Moreover, the accumulation of intracellular SPARC can drive imatinib resistance in chronic myelogenous leukemia cells ([@b29-mmr-17-05-6387]), and also modulate cisplatin resistance via modulating the Let-7f-1 miRNA/HMGB1 signaling in medulloblastoma cells ([@b30-mmr-17-05-6387]). *COL3A1* and *COL15A1*, two types of fibrillar collagen highly expressed in chemotherapeutic drugs resistant ovarian cancer cells ([@b31-mmr-17-05-6387]), were also exhibited to co-express, share protein domains, and co-localize with *COL4A1* ([Fig. 4A](#f4-mmr-17-05-6387){ref-type="fig"}). Additionally, *COL4A1* also was co-expressed, shared pathways, and had physical interactions with platelet derived growth factor subunit B (*PDGFB*). Akt/PDGF-B signaling can regulate Akt, and thus confer the hypoxia-induced cisplatin resistance in liver cancer cells ([@b32-mmr-17-05-6387]). PDGFB may contribute to the resistant phenotype and sustain signaling through MAPK and Akt in breast cancer cells ([@b33-mmr-17-05-6387]). The Coremine Medical database is a freely available online tool for obtaining information on health, medicine, and biology ([@b33-mmr-17-05-6387]); thus, we used this database to annotate the biological process of *COL4A1*. As shown in [Fig. 4C](#f4-mmr-17-05-6387){ref-type="fig"}, 12 biological processes significantly associated with *COL4A1*, gastric cancer, and drug resistance (P\<0.01) were annotated. Considering that the close relationships of *COL4A1* with these processes and the close relationships of the 12 processes with gastric cancer and drug resistance, *COL4A1* might be involved in the development of drug resistance in gastric cancer via its effect on these biological processes. In detail, cell growth related biological processes (including 4 cell growth, cell proliferation, and apoptotic process), gene expression regulation-related (including gene expression, RNA interference, and reverse transcription), and especially, the epithelial-mesenchymal transition (EMT) biological process were identified to be closely associated with the development of *COL4A1* in the gastric cancer drug resistance. Therefore, these results suggest that *COL4A1* may confer drug resistance in gastric cancer via regulating cell growth, gene expression, and in particular, epithelial mesenchymal transition (EMT) processes.

### Drug resistance function of COL4A1 is further validated by analyzing functionality of miRNAs that target COL4A1 mRNA

Post-transcriptional gene expression regulated by miRNAs is important for multiple cellular processes during development and pathogenesis ([@b34-mmr-17-05-6387]). Amplification and overexpression of tumor-promoting miRNAs or genetic loss of tumor-suppressing miRNAs are tightly correlated with the development of cancer and chemotherapeutic resistance ([@b35-mmr-17-05-6387]). Therefore, studying target genes of miRNAs is a focus of interest due to the diagnostic and therapeutic relevance, and the gene functions can also be predicted according to functionality of these miRNAs targeting the gene ([@b36-mmr-17-05-6387]). To obtain the miRNAs targeting *COL4A1* mRNA, the miRNA-mRNA interaction analysis was performed by using the miRWalk. We identified 553 miRNAs predicted to transcriptionally target *COL4A1* mRNA, indicating the regulation of *COL4A1* by miRNAs. These miRNAs predicted by at least 8 of 9 prediction tools were then submitted to pathway enrichment using DIANA miRPath ([@b20-mmr-17-05-6387]). As shown in [Table I](#tI-mmr-17-05-6387){ref-type="table"}, the top 5 highly associated pathway were ECM-receptor interaction, TGF-β signaling pathway, viral carcinogenesis, proteoglycans in cancer, and Hippo signaling pathway, which are almost reported to be related with drug resistance ([@b37-mmr-17-05-6387]--[@b41-mmr-17-05-6387]). It has been established TGFβ signaling can activate autophagy process, and thereby lead to the oxaliplatin resistance in colorectal cancer ([@b38-mmr-17-05-6387]). In addition, the activation of Hippo signaling also contributes to the drug resistance and cancer relapse ([@b42-mmr-17-05-6387]). YAP, an effector of hippo signaling, has also been reported to alter clinical response of EGFR-tyrosine kinase inhibitors in lung cancer patients ([@b43-mmr-17-05-6387]). Furthermore, it has also been reported that inactivation of Hippo pathway can restore gemcitabine sensitivity among a variety of cancers ([@b44-mmr-17-05-6387]). In the present study, as shown in [Table II](#tII-mmr-17-05-6387){ref-type="table"}, 9 of top 10 miRNAs that target *COL4A1* mRNA were tightly associated with drug resistance in cancers ([@b45-mmr-17-05-6387]--[@b51-mmr-17-05-6387]). For instance, loss of intracellular miR-29b promotes cisplatin resistance in gastric cancer. Consistently, ectopic overexpression of miR-29b in cholangiocarcinoma cells can confer gemcitabine sensitivity to HuH28 cells ([@b45-mmr-17-05-6387]). MiR-506 overexpression can confer hydroxycamptothecin resistance in colon cancer cells by inhibiting PPARα expression ([@b50-mmr-17-05-6387]). Collectively, these data provide further supports for the drug resistance function of *COL4A1* in gastric cancer.

Discussion
==========

In the present study, based on the bioinformatics analysis of two microarray datasets including GSE26899 and GSE77346, *COL4A1*, which was overexpressed in gastric cancer tissues and trastuzumab-resistant gastric cancer cells, was identified as a potential gene that promotes gastric cancer and trastuzumab resistance. By combining the protein/gene interactions, biological process annotation, and miRNAs-mRNA interaction analyses, we showed that *COL4A1* may confer trastuzumab resistance in gastric cancer.

Traditional chemotherapy and newly targeted therapy are two important methods of cancer treatment; however, the clinical efficacy of both is largely limited due to the occurrence of subsequent drug resistance ([@b52-mmr-17-05-6387]). Mechanisms underlying drug resistance, such as alteration of drug targets or metabolism and genetic mutation ([@b11-mmr-17-05-6387]) have been elucidated. Similar to that in breast cancer, the HER2-positivity rate in gastric cancer can range from 20 to 42% ([@b53-mmr-17-05-6387]). However, although the benefits of trastuzumab against HER2-positive gastric cancer have been formally established ([@b3-mmr-17-05-6387],[@b53-mmr-17-05-6387]), trastuzumab resistance is almost inevitable and eventually leads to the therapeutic failure ([@b4-mmr-17-05-6387]). Interfering with the combination of trastuzumab and HER2 ([@b54-mmr-17-05-6387]) and constitutive dimerization of the HER2 receptor ([@b55-mmr-17-05-6387]) have been recognized as causes of trastuzumab resistance. Recently, abnormal expression of tumorigenesis or drug resistance-related genes, such as phosphatidylinositol 3-kinase/Akt signaling ([@b56-mmr-17-05-6387]) and insulin like growth factor 1 receptor ([@b57-mmr-17-05-6387]), has been also identified as the important mechanisms causing trastuzumab resistance. However, a comprehensive study of specific molecular mutation underlying trastuzumab resistance is still needed. Drug resistance-related genes identified from induced drug-resistant cancer cells may simply be a result of transcriptional changes that may be irrelevant to resistance mechanisms ([@b58-mmr-17-05-6387]). Thus, targeting these genes usually fail to translate into clinical practice ([@b21-mmr-17-05-6387]). It has been recently shown that the ability to acquire drug resistance can arise even before the malignant transformation stage. For instance, overexpression of telomerase or inactivation of p53 can contribute to the drug-resistant phenotype in pre-tumorigenic models ([@b22-mmr-17-05-6387]). Insulin-like growth factor signaling has also been deemed a factor that promotes both the development of various tumors and their resistance to chemotherapy ([@b59-mmr-17-05-6387],[@b60-mmr-17-05-6387]). This evidence thus reminds us that the genes playing a key role in both tumor development and subsequent drug resistance likely produce the essential molecule for drug resistance. Herein, through retrieving microarray datasets and employing subsequent bioinformatics analysis, *COL4A1* was validated as an important gene that drives trastuzumab resistance in gastric cancer.

The heterotrimers formed by COL4A1 and COL4A2 presents in almost all the basement membranes, which are a specialized form of the extracellular matrix. Besides that the basement membranes can mediate tissue compartmentalization and transfer environmental signals to epithelial cells ([@b61-mmr-17-05-6387]), it is also an important structural and functional component of blood vessels. Accordingly, mutations in *COL4A1* are pleiotropic and contribute to many diseases, such as myopathy, hemorrhagic stroke, and tumor progression ([@b62-mmr-17-05-6387]). Upregulated COL4A1 produced by bladder cancer cells plays pivotal roles in tumor invasion via induction of tumor budding, while overexpression of COL4A1 also contributes to breast cancer cells proliferation, which indicates targeting COL4A1 can be an attractive approach for cancer treatment ([@b63-mmr-17-05-6387],[@b64-mmr-17-05-6387]). Besides, COL4A1 has also been identified as one of biomarkers for prognosis of intrahepatic cholangiocarcinoma ([@b65-mmr-17-05-6387]). Given that an interaction between PDGFB and HIF-1α and an interplay between SPARC, BCL-2, and caspase-8 have been recognized to augment chemotherapy-induced apoptosis, and thereby inducing resistance ([@b32-mmr-17-05-6387],[@b66-mmr-17-05-6387]). Herein, our results suggest *COL4A1* can drive trastuzumab resistance in gastric cancer via multiple mechanisms, such as cell proliferation and miRNAs-mediated post-transcriptional modification. Consistent with our results, a previous study also reported the sustained EMT phenotype induced by prolonged trastuzumab treatment may lead to trastuzumab resistance in gastric cancer cells ([@b67-mmr-17-05-6387]). Small molecules that targeting drug resistance-related genes have shown promising clinical efficacy in cancer treatment. For instance, erbB3 overexpression drives paclitaxel resistance in breast cancer, MM-121/SAR256212, an erbB3-targeted antibody, was thus designed and shows augmented effect on paclitaxel resistance ([@b68-mmr-17-05-6387]). Activation of the PI3K pathway frequently occurs in cancers and leads to drug resistance, but clinical benefits of PI3K inhibitors have been modest to date. Fortunately, LEE011, a specific CDK 4/6 inhibitor currently under clinical development, has shown promising effects against PI3K inhibition resistance ([@b69-mmr-17-05-6387]). HER2-positive patients receiving trastuzumab may inevitably develop resistance due to excessive activation of the PI3K/AKT pathway. A phase 1 clinical trial has been performed to evaluate the efficacy of the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors; interestingly, MK-2206 is safe, and reversed the trastuzumab resistance in HER2-overexpressing patients ([@b70-mmr-17-05-6387]). Collectively, this evidence suggests that identification of drug-resistant genes through bioinformatics methods and subsequent design of small molecule drugs may have great potential.

In conclusion, our results show that *COL4A1* may confer trastuzumab resistance in gastric cancer via multiple mechanisms based on bioinformatics analysis. However, further investigations elucidating the drug resistance function of *COL4A1* in trastuzumab-resistant gastric cancer models are necessary.
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![Identification of DEGs from GSE26899 dataset. (A) Volcano plot of DEGs between gastric cancer tissues and surrounding normal tissues. Red dots represent significantly upregulated DEGs in gastric cancer tissues; green dots represent significantly downregulated DEGs in gastric cancer tissues; gray dots represent no significant difference. P\<0.05 and fold-change \>2 were regarded as significant. (B) GO analysis of significantly upregulated DEGs in gastric cancer tissues. Top 5 enriched GO categories under 'biological process', 'cellular component' and 'molecular function' were indicated. (C) KEGG pathway enrichment analysis of significantly upregulated DEGs in gastric cancer tissues. Top 5 enriched pathways were indicated. DEGs, differentially expressed genes; GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; ECM, extracellular matrix.](MMR-17-05-6387-g00){#f1-mmr-17-05-6387}

![Module with the highest score, obtained based on the DEGs identified from GSE26899 dataset. (A) Module with the highest score generated from the protein-protein interaction network of significantly upregulated DEGs in gastric cancer tissues. (B) Heat map of the 17 genes from the selected module. Red, upregulation; Blue, downregulation; DEGs, differentially expressed genes; COL, collagen; PLOD3, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3; SERPINH1, serpin family H member 1.](MMR-17-05-6387-g01){#f2-mmr-17-05-6387}

![*COL4A1* in the selected module is significantly upregulated in trastuzumab resistant gastric cancer cells. (A) Volcano plot of DEGs between trastuzumab-resistant and sensitive gastric cancer cells. Red dots represent significantly upregulated DEGs in trastuzumab-resistant gastric cancer cells; green dots represent significantly downregulated DEGs in trastuzumab-sensitive gastric cancer cells; and gray dots represent no significant difference. P\<0.05 and fold-change \>2 were regarded as significant. (B) The expression of *COL4A1* in normal gastric tissue and gastric cancer tissue, respectively. Representative immunohistochemistry staining results were obtained from the Human Protein Atlas online database (magnification, ×40). The relative mRNA level of *COL4A1* was validated by two other datasets including (C) GSE54129 and (D) GSE65801. The values are expressed as the mean ± standard deviation. \*\*P\<0.01, as indicated. (E) Proportion of genetic alterations of *COL4A1* retrieved from the cBioportal (n=393; [www.cbioportal.org/](www.cbioportal.org/)). (F) Kaplan-Meier survival analysis of *COL4A1* in gastric cancer patients that was obtained from [www.kmplot.com](www.kmplot.com). HR, hazard ratio; DEGs, differentially expressed genes; *COL4A1*, collagen type IV α1.](MMR-17-05-6387-g02){#f3-mmr-17-05-6387}

![Validation of drug resistance function of *COL4A1*. (A) Protein/gene-protein/gene interaction network of *COL4A1* generated using the GeneMANIA online tool. The network legends refer to the interaction types between proteins/genes. The interaction types between proteins/genes were illustrated as indicated by the network legend. (B) Relative mRNA level of 6 genes interacting with *COL4A1* based on the microarray data of GSE77346. Red column, relative expression \>1; Black column, relative expression \<1. (C) Annotation of biological processes of *COL4A1* with gastric cancer and drug resistance using the Coremine Medical online tool. DEGs, differentially expressed genes; *COL4A1*, collagen type IV α1.](MMR-17-05-6387-g03){#f4-mmr-17-05-6387}

###### 

Top 8 enriched pathways regulated by microRNAs that target collagen type IV α1 mRNA and their associations with drug resistance in gastric cancer.

  Author, year              miRNAs (hsa-miR-)                                                                                                                                                                   KEGG pathway               P-value        Regulation of drug resistance in cancers   (Refs.)
  ------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------- -------------- ------------------------------------------ -------------------------
  Wu *et al*, 2017          29b-3p, 124-3p, 148a-3p, 29a-3p, 152-3p, 148b-3p, 506-3p, 628-5p, 29c-3p, 767-5p, 637, 33a-5p, 33b-5p, 203a, 374a-5p, 300, 106a-5p, 98-5p, 381-3p, let-7b-5p, 7c-5p, 7b-3p, 7a-5p   ECM-receptor interaction   1.14×10^‒15^   Yes                                        ([@b37-mmr-17-05-6387])
  Sun *et al*, 2017                                                                                                                                                                                             TGF-β signaling pathway    6.58×10^‒11^   Yes                                        ([@b38-mmr-17-05-6387])
  --                                                                                                                                                                                                            Viral carcinogenesis       9.72×10^‒11^   None                                       --
  Lanzi *et al*, 2017                                                                                                                                                                                           Proteoglycans in cancer    3.94×10^‒10^   Yes                                        ([@b39-mmr-17-05-6387])
  Gujral *et al*, 2017                                                                                                                                                                                          Hippo signaling pathway    6.66×10^‒10^   Yes                                        ([@b44-mmr-17-05-6387])
  Lee *et al*, 2015                                                                                                                                                                                             Cell cycle                 1.01×10^‒9^    Yes                                        ([@b40-mmr-17-05-6387])
  Wallerand *et al*, 2010                                                                                                                                                                                       Adherens junction          2.99×10^‒8^    Yes                                        ([@b41-mmr-17-05-6387])
  --                                                                                                                                                                                                            Pathways in cancer         3.46×10^‒8^    Cancer pathway                             --

The miRNAs predicted by at least 7 of the 9 prediction tools were submitted to DIANA-miRPath version 3.0 to perform KEGG analysis. miRNA/miR, microRNA; KEGG, Kyoto Encyclopedia of Genes and Genomes; ECM, extracellular matrix; TGF, transforming growth factor.

###### 

Top 11 microRNAs targeting collagen type IV α1 mRNA predicted by microRNA-mRNA interactions, and their drug resistance-associated functions in cancer.

                                        miRNA-mRNA prediction tools                                                             
  ----------------------- ------------- ----------------------------- --- --- --- --- --- --- --- --- ------------------------- -------------------------
  Okamoto *et al*, 2013   miR-29b-3p    1                             1   1   1   1   1   1   1   1   Drug resistance-related   ([@b45-mmr-17-05-6387])
  Liu *et al*, 2016       miR-124-3p    1                             1   1   1   1   1   1   1   1   Drug resistance-related   ([@b46-mmr-17-05-6387])
  Chen *et al*, 2017      miR-148a-3p   1                             1   1   1   1   1   1   1   1   Drug resistance-related   ([@b47-mmr-17-05-6387])
  Zhong *et al*, 2013     miR-29a-3p    1                             1   1   1   1   1   1   1   1   Drug resistance-related   ([@b48-mmr-17-05-6387])
  Chen *et al*, 2017      miR-152-3p    1                             1   1   1   1   1   1   1   1   Drug resistance-related   ([@b47-mmr-17-05-6387])
  Sui *et al*, 2015       miR-148b-3p   1                             1   1   1   0   1   1   1   1   Drug resistance-related   ([@b49-mmr-17-05-6387])
  Tong *et al*, 2011      miR-506-3p    1                             1   1   1   1   1   0   1   1   Drug resistance-related   ([@b50-mmr-17-05-6387])
  --                      miR-628-5p    1                             1   1   0   1   1   1   1   1   Drug resistance-related   --
  Zhang *et al*, 2013     miR-29c-3p    1                             1   1   1   1   1   0   1   1   Drug resistance-related   ([@b51-mmr-17-05-6387])
  --                      miR-767-5p    0                             1   1   1   1   1   1   1   1   Drug resistance-related   --
  --                      miR-637       1                             1   1   1   0   1   1   1   1   Drug resistance-related   --

A, miRWalk; B, miRanda; C, miRDB; D, miRNAMap; E, Pictar2; F, PITA; G, RNA22; H, RNAhybrid; I, TargetScan; miRNA/miR, microRNA.

[^1]: Contributed equally
